Tango Therapeutics Stock Forecast

Stock Price Forecast

According to 13 analysts polled by S&P Global, Tango Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $44.75. The average 1-year stock price forecast is 87.40% higher than the current stock price, while the lowest is $24 (+0.50%) and the highest is $69 (+188.94%).

Price Target: $44.75 (+87.40%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$24	$44.75	$40	$69
Change	+0.50%	+87.40%	+67.50%	+188.94%

Analyst Ratings

The average analyst rating for Tango Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	Mar '26	Apr '26	May '26	Jun '26	Jul '26	Aug '26
Strong Buy	9	10	9	11	11	11
Buy	1	1	0	0	1	1
Hold	1	1	3	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	11	12	12	12	13	13

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Robert Burns H.C. Wainwright	H.C. Wainwright	Buy Reiterates $66 → $68	Buy	Reiterates	$66 → $68	+184.76%	Aug 18, 2026
Laura Prendergast Stifel Nicolaus	Stifel Nicolaus	Buy Maintains $40	Buy	Maintains	$40	+67.50%	Aug 17, 2026
Robert Driscoll Wedbush	Wedbush	Buy Reiterates $33 → $39	Buy	Reiterates	$33 → $39	+63.32%	Aug 12, 2026
Michael Schmidt Guggenheim	Guggenheim	Buy Reiterates $32 → $35	Buy	Reiterates	$32 → $35	+46.57%	Aug 12, 2026
John Newman Canaccord Genuity	Canaccord Genuity	Buy Maintains $46	Buy	Maintains	$46	+92.63%	Aug 11, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

from 62.38M

-100.00%

from 62.38M

Revenue Next Year

2.62M

EPS This Year

-1.38

from -0.87

EPS Next Year

-1.63

from -1.38

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	37.04M	24.86M	36.53M	42.07M	62.38M	-
Revenue Growth	383.83%	-32.89%	46.93%	15.17%	48.29%	-100.00%
Operating Income	-58.19M	-111.07M	-114.17M	-145.60M	-111.29M	-234.27M
Net Income	-58.24M	-108.18M	-101.74M	-130.30M	-101.59M	-217.40M
EPS	-	-	-	-	-0.87	-1.38
Free Cash Flow	-34.02M	-48.74M	-61.82M	-67.27M	-60.86M	-169.50M
No. Analysts	-	-	-	-	-	12

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	-100.0%
Avg	-100.0%
Low	-100.0%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-1.17
Avg	-1.38
Low	-1.57

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-